PS01 - Guided Poster Session
Thursday 3 October
17:30 - 18:30
Room: Olympia Foyer

Chairs: Elias Eriksson, University of Gothenburg, Sweden; Joseph Zohar, Sheba Medical Center, Israel; Pierre Blier, University of Ottawa, Canada; Ioannis Diakogiannis, Aristotle University of Thessaloniki, Greece

**Topic: Mood**

PS01.01 - Comparison of Circulating endothelial progenitor cells among patients with mood disorders and normal controls
Ya Mei Bai, National Yang Ming University, Taipei Veterans General Hospital, Taipei, Taiwan

PS01.02 - Connectome study at resting state in bipolar disorder using magnetoencephalography
Yuichi Takei, Gunma University, Mabashi, Japan

PS01.03 - Patient-reported outcomes in major depressive disorder with suicidal ideation: a real-world data analysis using PatientsLikeMe platform
Stephane Borentain, Janssen Research & Development, LLC, Titusville, USA

PS01.04 - Randomized, double-blind, placebo-controlled study to Investigate the Effect of Vorioxetine in AD patients with depression
Do Hoon Kim, Chuncheon Sacred Heart Hosp. Dept. of Psychiatry, Hallym University , Chuncheon, South Korea

PS01.05 - Vital exhaustion and stroke: gender disparities. WHO epidemiological program MONICA-psychosocial
Dmitriy Panov, Institute of Internal and Preventive Medicine - branch of Institute of Cytology and Genetics, Novosibirsk, Russia

PS01.06 - Improving Emotion Regulation and Mood and Reducing Suicide Risk in Bipolar Disorder by Regularizing Daily Rhythms
Hilary Blumberg, Yale School of Medicine, New Haven, USA

PS01.07 - Does LSD have antidepressive potentials? Lessons to be learned from early psychedelic therapy in Denmark
Jens Knud Larsen, Aarhus University Hodspital, Aarhus, Denmark
PS01.08 - A Phase 3, Double-Blind, Placebo-Controlled Trial of the Neuroactive Steroid SAGE-217 in Postpartum Depression: Assessment of Depressive Symptoms Across Multiple Measures

Stephen Kanes, SAGE Therapeutics, Inc., Cambridge, USA

PS01.09 - Efficacy and Safety of the Neuroactive Steroid Brexanolone in Women with Postpartum Depression: Integrated Analyses of Clinical Data

Sonmi Park, Sage Therapeutics, Zug, Switzerland

PS01.10 - Aberrant cortical connectivity revealed by the heartbeat evoked magnetic fields (HEFs) in patients with mood disorders

Yutaka Kato, Tsutsuji Mental Hospital, Tatebayashi, Japan

PS01.11 - SAGE-217 a First in Class Neuroactive Steroid and GABA_A Receptor Positive Allosteric Modulator being developed for Major Depressive Disorder: A Multicenter, Randomized, Double-blind, Pivotal Placebo-controlled Trial

Stephen Kanes, SAGE Therapeutics, Inc, Cambridge, USA

PS01.12 - Changes in the connectome according to body mass index in healthy females: a magnetoencephalography study

Masashi Suda, Gunma University Graduate School of Medicine, Maebashi, Japan

PS01.13 - Suicide attempt is highly associated with extreme cold environments and molecular pathways of cancer

Christina Kyriakou, University of Cyprus, Medical School, Nicosia, Cyprus

PS01.14 - Unique Pharmacology and Clinical Evidence Supporting the Antidepressant Therapeutic Potential of Lumateperone

Torgny H. Svensson, Karolinska Institutet, Stockholm, Sweden

PS01.15 - Association between human in vivo metabotropic glutamate receptor-5 availability and white matter microstructural integrity: a multimodal imaging study

Jong-Hoon Kim, Gachon University College of Medicine, Gil Medical Center, Incheon, South Korea

PS01.16 - Effects of Nx4 on stress-induced amygdala-centered resting state functional connectivity

Meng Li, Clinical Affective Neuroimaging Laboratory, Tübingen, Germany

PS01.17 - Nx4 influences association of EEG with amygdala activation and connectivity after stress

Nooshin Javaheripour, Universitäts Klinikum Tübingen, Tübingen, Germany
PS01.18 - Bright light therapy in seasonal affective disorder – a meta-analysis of available evidence
Edda Winkler-Pjrek, Medical University of Vienna, Vienna, Austria

PS01.19 - Depression in patients with psychosis - impact on treatment motivation and satisfaction
Dietmar Winkler, Medical University of Vienna, Vienna, Austria

PS01.20 - Interaction of PSD95 with GluN2B subunit in different conditions of cocaine forced abstinence in rat brain structures
Irena Smaga-Maślanka, Jagiellonian University Medical College, Kraków, Poland

PS01.21 - Vitamin D3 modulates depression-like behavior and expression of NF-Kb and 17β-estradiol receptor in adult ovariectomized rat exposed to unpredictable chronic mild stress
Aleksandra Koshkina, ITMO University, St. Petersburg, Russia

PS01.22 - Co-administration of Vitamin D3 and escitalopram attenuates depression-like behavior and modulates BDNF, NT-3 and NT-4 expressions in the hippocampus of the adult ovariectomized rats subjected to chronic unpredictable stress
Julia Fedotova, I.P. Pavlov Institute of Physiology RAScI, St. Petersburg, Russia

PS01.23 - Hostility as a risk factor for suicide attempts in patients with major depressive disorder
Kyoung-Uk Lee, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

PS01.24 - The Monoamine Oxidase Inhibitor Isocarboxazid: A clinical update
Jens Knud Larsen, Aarhus University Hospital, Aarhus, Denmark

PS01.25 - Ketamine eliminates suicidal ideation in MDD patients associated with kynurenine metabolism mediating brain activity of middle temporal gyrus
Bin Zhang, Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China

PS01.26 - Plasma Serotonin Levels Correlated with Depressive Symptoms in Major Depressive Disorder
Chao Deng, School of Medicine, University of Wollongong, Wollongong, Australia

PS01.27 - Employment Status and Pharmacotherapy of Japanese Outpatients With Mood Disorders
Yukinori Kamata, Department of Psychiatry, School of Medicine, Showa University, Setagaya-ku, Tokyo, Japan
PS01.28 - The role of oxytocin in suicidal behavior of male and female affective disorder patients
Marleen Margret Mignon Mitschek, Medical University of Vienna, Vienna, Austria

PS01.29 - Association of Heart Rate Variability with Psychiatric Disturbances in Patients with Multiple Sclerosis and Neuromyelitis Optica
Joon Sung Shin, Seoul National University Hospital, Seoul, South Korea

PS01.30 - The Hamilton Depression Rating Scale Measures Side Effects and Therefore Underestimates the Antidepressant Effect of SSRIs and SNRIs
Fredrik Hieronymus, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden

PS01.31 - LY341495 induces antidepressant-like effects in the chronic unpredictable stress model of depression in C57BL/6J mice and enhances the antidepressant action of ketamine in this model
Agnieszka Pałucha-Poniewiera, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland

PS01.32 - Zinc Deficiency: An essential Variable for the Induction of Resistance to Antidepressants
Anna Rafało-Ulińska, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland

PS01.33 - Increased adrenocorticotropic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder.
Ji Hyun Yoo, Samsung Medical Center, Seoul, South Korea

PS01.34 - Ratio of Plasma BDNF to Leptin Levels are Associated with Treatment Response in Major Depressive Disorder but Not in Panic Disorder: A 12-Week Follow-up Study
Dong Yeun Yook, Samsung Medical Center, Seoul, South Korea

PS01.35 - Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: a 12-week follow-up study
Hong Jin Jeon, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

PS01.36 - Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.
Seonah Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
PS01.37 - Predictors of alcohol use disorder in acutely depressed patients across unipolar and bipolar spectrum.
Minseok Hong, Seoul National University Hospital, Seoul, South Korea

PS01.38 - Biomarkers of depression in skin – a pre-clinical approach
Erik Kaadt, Aarhus University - Department of Clinical Medicine - Translational Neuropsychiatry Unit, Aarhus, Denmark

PS01.39 - Double-blind, placebo-controlled Phase 1 Single Ascending Dose Study of SAGE-718
Stephen Kanes, SAGE Therapeutics, Inc, Cambridge, USA

**Topic: Insomnia**

PS01.40 - Psychophysiological Characteristics of Insomnia Patients Measured by Biofeedback System
Sung Young Huh, Pusan National University Yangsan Hospital, South Korea

PS01.41 - Treatment of insomnia in the elderly: a systematic review and meta-analysis
Myrto Samara, Dept. of Psychiatry and Psychotherapy, TU-München, Munich, Germany

PS01.42 - Psychosocial Intervention for Discontinuing Benzodiazepine Hypnotics in Patients with Chronic Insomnia: A Systematic Review and Meta-analysis
Yoshikazu Takaesu, Kyorin University, Tokyo, Japan

PS01.43 - Polysomnographic Features of Opiate Use Disorder
Ahmed Elsheshai, Maamoura Psychiatric Hospital, Alexandria, Egypt

PS01.44 - Perampanel in patients with resistant insomnia without epilepsy
Eugenio Suarez Gisbert, University Hospital Infanta Sofia, San Sebastian De Los Reyes, Spain

PS01.45 - Depression Anxiety outcome: Insomnia, Headache and to-date treatments
Habib A. Rabbani, Ste Anne University Hospital, Paris, France

**Topic: Other**
PS01.46 - The neural substrates of risky rewards and losses across healthy volunteers and patient group using PET imaging
Nikolina Skandali, University of Cambridge Department of Psychiatry, Cambridge, UK

PS01.47 - Disrupted local and distal functional connectivity development in the supramarginal gyrus in 3 to 10 year old children with autism spectrum disorder: A cross-sectional study
Narae Yoon, Department of Neuropsychiatry, Seoul National University Hospital, Seoul, South Korea

PS01.48 - Vafidemstat: An epigenetic drug with emerging therapeutic potential, composite data from three psychiatric disorders from the REIMAGINE trial
Josep Antoni Ramos-Quiroga, Hospital Universitario Valle de Hebrón, Valle de Hebrón Research Institute (VHRI), Barcelona, Spain

PS01.49 - Preliminary stress exposures are modify the side effects of glucocorticoids drug Triamcinolone Acetonide in respect to behavior activity, thymus and adrenal glands involution in Wistar rats
Vadim Tseylikman, South Ural State University, Chelyabinsk, Russia

PS01.50 - Ghrelin in brain reward circuits
Eliot Gardner, U.S. National Institute on Drug Abuse (NIH), Baltimore, USA

PS01.51 - Impulsivity in Gambling Disorder and Problem Gambling: A Meta-analysis
Roxanne Hook, University of Cambridge, Cambridge, UK

PS01.52 - A Literature Overview of Virtual Reality (VR) in Treatment of Psychiatric Disorders: Recent Advances and Limitations
Mi Jin Park, Samsung Medical Center, Seoul, South Korea

PS01.53 - Choosing wisely of Apolipoprotein E genetic testing in Alzheimer’s disease
Hyunju Yang, Jeju-si, South Korea

PS01.54 - Low Diastolic Blood Pressure and Cognitive Decline in Korean Elderly People: The Korean Longitudinal Study on Cognitive Aging and Dementia
Dongyun Lee, Gyeongsang National University Changwon Hospital, Changwon, South Korea
PS01.55 - Early menarche as a risk factor for suicidal ideation in girls: The Korea Youth Risk Behavior Web-Based Survey
You Jung Han, SAMSUNG Changwon Hospital, Changwon, South Korea

PS01.56 - Suicide trends in Cyprus between 2004-2017
Christina Kyriakou, University of Cyprus, Medical School, Nicosia, Cyprus

PS01.57 - Transition Care Program at Hospital Universitario de la Princesa, Madrid
Clara Sanahuja Muñoz, Hospital Universitario la Princesa, Madrid, Spain

PS01.58 - Anxiogenic effect of glucocorticoid drug Triamcinolone Acetonide and alteration in monoamines content in neocortex and hippocampus in rats with low intensity of microsomal oxidation
Olga Tseylikman, South Ural State University, Chelyabinsk, Russia

PS01.59 - PTSD and neurocognitive functioning: Controlling the effects of insomnia and depression
Kyeong-Sook Choi, Eulji University School of Medicine, Daejeon, South Korea

PS01.60 - Strain difference in the side effects of the glucocorticoid drug on the thymus between normal and hypertensive rats: focus on the previous stress exposures
Mariya Komelkova, South Ural State University, Chelyabinsk, Russia

PS01.61 - Correlation Between Specific Component of Mental Health and Psychological Well-Being of Filipino Older People
Perry Espinosa, Woosong College, Daejeon, South Korea

PS01.62 - Does down-regulation of 5-HT2A receptors contribute to subchronic SSRI administration reducing context-conditioned fear in rat?
Melker Hagsäter, Institute of Neuroscience and Physiology, Gothenburg, Sweden

PS01.63 - Protracted Abstinence Syndrome in Recovering Opiate Addicts
Ahmed Elsheshai, Maamoura Psychiatric Hospital, Alexandria, Egypt

PS01.64 - Spatial co-expression of genes with the enzyme monoamine oxidase A in the human cerebral cortex: a PET and AHBA study
Godber Mathis Godbersen, Department of Psychiatry and Psychotherapy, Vienna, Austria

PS01.65 - Non-psychotic mental disorders in patients with hyperthyroidism and their combined treatment
Olena Pityk, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
PS01.66 - Behavioral cross-sensitization between cocaine and ethanol is accompanied by parallel changes in the activity of AMPK system
Hyun Soo Ji, Seoul National University Hospital, Seoul, South Korea

PS01.67 - Impairments in Cognition in Cannabis Dependent Young Adults
Ayla Selamoglu, University of Cambridge, Cambridge, UK

PS01.68 - Whole-brain imaging and analysis to reveal spatial pattern of Amyloid β plaques.
Hiroaki Ono, University of Tokyo, Tokyo, Japan

PS01.69 - The Case of Severe Alprazolam Addiction
Olena Pityk, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine

PS01.70 - Socio-demographic and clinical variables associated with the implementation of add-on treatment strategies in unipolar depression – a naturalistic European multicenter investigation
Markus Dold, Medical University of Vienna, Wien, Austria

PS01.71 - Antidepressive therapy has no effect on ciliary neurotrophic factor concentration in blood serum of patients with melancholic depression.
Marat Uzbekov, Moscow Research Institute of Psychiatry, Moscow, Russia

**PS02 - Guided Poster Session**
Friday 4 October
17:30 - 18:30
Room: Olympia Foyer

Chairs: Konstantinos Fountoulakis, Aristotle University of Thessaloniki, Greece; Gabriella Gobbi, McGill University, Canada; Francesc Artigas, CSIC, Spain; Agorastos Agorastos, Aristotle University of Thessaloniki, Greece

**Topic: ADHD**

PS02.01 - A Study on the School Violence Experience of Children with Attention Deficit Hyperactivity Disorder in the Context of Bullying
Sung Young Huh, Pusan National University Yangsan Hospital, South Korea
PS02.02 - Symptoms of Attention-Deficit/Hyperactivity Disorder in Korean elementary school children
Kyung Kyu Lee, Dept. of Psychiatry, Dankook University Hospital, Cheonan, ChungNam, South Korea

PS02.03 - Long-Term Effects of Attention-Deficit Hyperactivity Disorder Medication on Growth in the Korean School-Aged Boys with Attention-Deficit Hyperactivity Disorder
Kanguk Lee, Kangwon National University Hospital, Chuncheon, South Korea

PS02.04 - Radixin in the nucleus accumbens contributes to choice preference toward risk in rat gambling task
Jong Woo Park, Yonsei University College of Medicine, Seoul, South Korea

PS02.05 - Differential Activity and Functional Coupling to the Prefrontal cortex of Dopamine Neurons in the Ventral Tegmental Area in the WKY/NCrl and SHR/NCrl Animal Models of ADHD
Ike De La Peña, Loma Linda University, Loma Linda, USA

PS02.06 - Specific psychiatric symptoms, social functions, and pharmacotherapy of Japanese adult outpatients with neurodevelopmental disorders
Hiromitsu Uno, Department of Psychiatry, School of Medicine, Showa University, Setagaya-ku, Tokyo, Japan

PS02.07 - Delayed maturation hypothesis in SHR model of ADHD in terms of brain network topology
Soomin Jang, Seoul National University Hospital, Seoul, South Korea

PS02.08 - Peripheral mitochondrial DNA copy numbers are increased in Korean attention-deficit hyperactivity disorder
Yebin D Ahn, Seoul National University Hospital, Seoul, South Korea

PS02.09 - Chronic valproic acid reduces compulsivity and contributes to choice preference toward risk in a rat gambling task
Min Jeong Ku, Yonsei University College of Medicine, Seoul, South Korea

PS02.10 - ADHD medication and behavioral and neuropsychiatric outcomes: real-world evidence from pharmacoepidemiology studies
Zheng Chang, Karolinska Institutet, Stockholm, Sweden

PS02.11 - Clinical predictors of response to methylphenidate in adult Attention Deficit Hyperactivity Disorder: preliminary results from a longitudinal, naturalistic study.
Ana Velosa, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal
PS02.12 - The associations between prenatal maternal obesity and fetal prefrontal functional connectivity.

Carly Lenniger, NYU Langone Health, New York, USA

PS02.13 - Comparative Cognitive Effects of Methylphenidate, Guanfacine, and the Combination in Children with ADHD

James McCracken, UCLA Semel Institute, Los Angeles, USA

**Topic: Mood**

PS02.14 - Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study

Dong Jun Kim, Samsung Medical Center, Seoul, South Korea

PS02.15 - Effects of low-grade inflammation on functional brain networks

Jungyoon Kim, Ewha Brain Institute, Ewha W. University, Seoul, South Korea

PS02.16 - A data-driven approach to the identification of risk factors for future addictive disorder: network-based neurobiological model for predicting addiction-proneness

In Kyoon Lyoo, Ewha Brain Institute, Ewha W. University, Seoul, South Korea

PS02.17 - Investigation of Selected microRNA in a Chronic Mild Stress Model

Louise Sand Kirk, Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

PS02.18 - Dysmorphophobia: Evolution or Involution?

Clara Sanahuja Muñoz, Hospital Universitario la Princesa, Madrid, Spain

PS02.19 - Topological co-expression of AGBL1, ANXA8 and BDNF with the serotonin-1A receptor quantified by PET in the human brain

Jakob Unterholzner, Medical University of Vienna, Vienna, Austria

PS02.20 - Pharmacological treatment of 124,404 patients diagnosed with major depressive disorder at Danish psychiatric hospitals in the period from 1995 to 2016

Søren Dinesen Østergaard, Department of Psychiatry, Aarhus University Hospital, Aarhus, Denmark
PS02.21 - Greater right frontal activity and its related symptom severity in manic patients
Vin Ryu, National Center for Mental Health, Seoul, South Korea

PS02.22 - Chronic restraint stress-induced depression-like behavior is mediated by up-regulation of melanopsin expression in C57BL/6 mice retina
Yingmei Fu, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

PS02.23 - Factors associated with the severity of treatment refractory depression
Kazuhiro Nozaki, Kyorin University School of Medicine, Tokyo, Japan

PS02.24 - Evaluation of α5 GABA-NAMs in animal models of depression
Astrid Hylgaard Bach, Translational Neuropsychiatry Unit, Aarhus University, Aarhus, Denmark

PS02.25 - Patterns of Protein Expression and Correlation in Mononuclear Blood Cells for Lithium Treatment Response of Bipolar Disorder: a Flow Cytometry Study
Keming Gao, Case Western Reserve University, Cleveland, USA

PS02.26 - Ketamine modulates striatal activity to reward magnitude 2 hours after its administration: an fMRI study in unmedicated, remitted depressed volunteers.
Vasileia Kotoula, Centre for Neuroimaging Sciences, IoPPN, London, UK

PS02.27 - Proof of concept for a newly identified target, 11-beta-hydroxysteroiddehydrogenase type 2, to treat therapy refractory depression – the effect of glycyrrhizin on treatment outcome
Harald Murck, Philipps-University Marburg, Marburg, Germany

PS02.28 - Another view at the Major Depressive Disorder biomarkers
Michaela Krivosova, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic

PS02.29 - Brain SPECT Pre-Post Magnetic Seizure Therapy (MST) for Major Depressive Disorder as a Marker of Remission
Meghan Peterson, Medical College of Georgia at Augusta University, Augusta, USA

PS02.30 - Bearing of maternal prenatal stress on the developing fetal brain and timing of delivery
Moriah Thomason, Department of Child and Adolescent Psychiatry, New York University Medical Center, New York, USA
PS02.31 - Double-Blinded Randomized Pilot Clinical Trial Comparing Cognitive Side Effects & Antidepressant Efficacy of Standard Right Unilateral ECT versus Low Amplitude Seizure Therapy (LAP-ST)

Nagy Youssef, Medical College of Georgia at Augusta University, Augusta, USA

PS02.32 - Adjunctive antidepressant treatment for acute bipolar depression: Findings from the Bipolar CHOICE trial

Ole Köhler-Forsberg, Department of Psychiatry, Aarhus University Hospital, Aarhus, Denmark

PS02.33 - Effect of combined treatment with SSRIs and renin-angiotensin system (RAS) drugs: Population-based and propensity-score matched cohort study

Ole Köhler-Forsberg, Department of Psychiatry, Aarhus University Hospital, Aarhus, Denmark

PS02.34 - Clinical correlates of comorbid hypertension in patients with major depression

Gernot Fugger, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

PS02.35 - Pharmacogenomics in the Service of Personalized Psychopharmacology

Angelos Halaris, Loyola University Stritch School of Medicine, Maywood, USA

PS02.36 - Comparing cognitive side effects & antidepressant efficacy of Focal Electrically Administered Seizure Therapy (FEAST) versus standard ultra-brief Right Unilateral (RUL) ECT: A two-site clinical trial

Nagy Youssef, Medical College of Georgia at Augusta University, Augusta, USA

PS02.37 - Comparison of serum microbiome composition between bipolar disorder and major depressive disorder

Sang Jin Rhee, Seoul National University Hospital, Seoul, South Korea

PS02.38 - The Combination Therapy of ECT and Aripiprazole for Treatment Resistant Schizophrenia with Dopamine Supersensitivity Psychosis

Masahiko Nishimoto, Soushu Hospital, Atsugi, Japan

**Topic: Psychosis**

PS02.39 - Two-sample Mendelian randomization study for schizophrenia and breast cancer

Woojae Myung, Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
PS02.41 - Treatment satisfaction with paliperidone palmitate in patients with current oral atypical antipsychotics
Geli Marie Chauca Chauca, Hospital Infanta Margarita, Cabra, Córdoba, Spain

PS02.42 - Dysregulated insulin family member expression is associated with adult neurogenesis and inflammation in the human subependymal zone in schizophrenia and bipolar disorder
Christin Weissleder, Neuroscience Research Australia, Sydney, Australia

PS02.43 - 20-year follow-up study on antipsychotic treatment, physical morbidity, and mortality in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
Jari Tiihonen, Karolinska Institutet, Stockholm, Sweden

PS02.44 - Development Update on Pimavanserin, a 5-HT2A Receptor Inverse Agonist
Dragana Bugarski-Kirola, ACADIA Pharmaceuticals Inc., Princeton, USA

PS02.45 - Delayed effect of NMDA receptor blockade on forebrain network oscillations in rats
Linn Jansson, Dept Psychiatry-BIDMC, Harvard Medical School, Boston, USA

PS02.46 - Respiratory synchrony in the acute ketamine model of schizophrenia in rats
Rola Mofleh, Dept Psychiatry-BIDMC, Harvard Medical School, Boston, USA

PS02.47 - Patterns of Antipsychotic Medication Prescribing in Australia
Nagesh Pai, University of Wollongong, Wollongong, Australia

PS02.48 - Patient Persistence on Antipsychotic Medications in Australia
Nagesh Pai, University of Wollongong, Wollongong, Australia

PS02.49 - Sex-specific transcriptional and proteomic signatures in schizophrenia
Jari Tiihonen, Karolinska Institutet, Stockholm, Sweden

PS02.50 - Vortioxetine for negative symptoms of schizophrenia: from theory to practice
Antonios Paraschakis, Psychiatric Hospital of Attica "Dafni", Athens, Greece

PS02.51 - Management of risperidone-induced hyperprolactinaemia.
Anastasia Kokkali, Dromokaiteio Psychiatric Hospital, Athens, Greece

PS02.52 - Impact of a GWAS SNP in MIR137 on neurodevelopment in a novel CRSPR mouse model for schizophrenia
Mengyi Xu, Centre For Addiction and Mental Health, Toronto, Canada
PS02.53 - Striatal Glutathione Levels and their Apparent Upregulation in First-episode Psychosis Patients: A Pilot In Vivo 1H MRS Study
Dikoma Shungu, Weill Cornell Medicine, New York, USA

PS02.54 - An Approach to reaction time in patients suffering from schizophrenia
Ioannis Apostolopoulos, Dromokaitio, Athens, Greece

PS02.55 - Two novel loci associated with antipsychotics response in Chinese Han population
Qingqing Xu, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

PS02.56 - Population Coding of Multiple Types of Information in Dentate Gyrus
Ryuichi Nakajima, Division of Systems Medical Science, Fujita Health University, Toyoake, Japan

PS02.57 - 12-month Greek prospective non-interventional multicenter study for early stage schizophrenia treatment with once monthly Paliperidone Palmitate
Konstantinos Samaras, Janssen-Cilag Pharmaceutical SACI Greece, Athens, Greece

PS02.58 - Dopamine signaling and dyslipidemia in first episode psychosis
Irene Graf, Medical University of Vienna, Vienna, Austria

PS02.59 - Functional coupling between M₁ muscarinic acetylcholine receptors and Galpha(q/11) proteins distortedly distributed only in schizophrenic patients: A postmortem study
Yuji Odagaki, Department of Psychiatry, Faculty of Medicine, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan

PS02.60 - XEUS STUDY: A non-interventional, multicenter, retrospective study of schizophrenia patients treated with Paliperidone Palmitate Once Monthly in Greece
Dimos Dimellis, “Ego Ideal” Private Institute of Mental Health, Thessaloniki, Greece

PS02.61 - The efficacy and safety of brexipiprazole in Japanese patients with schizophrenia at acute phase; A retrospective study
Yasutaka Fujita, Kusatsu Hospital, Hiroshima, Japan

PS02.62 - Obesity, psychosis and lower grey matter volumes in cerebellum
Marian Kolenic, National Institute of Mental Health, Klecany, Czech Republic
PS02.63 - Improved of negative symptoms and metabolic rates in schizophrenic patients treated with paliperidone palmitate long-acting injection
Eugenio Suarez Gisbert, University Hospital Infanta Sofia, San Sebastian De Los Reyes, Spain

PS02.64 - Evaluation of bone demineralization risk in patients with iatrogenic hyperprolactinemia by antipsychotics: preliminary data.
Angel Luis Montejo, University of Salamanca, Salamanca, Spain

PS02.65 - A case of Ekbtom Syndrome successfully treated with aripiprazol
Eugenio Suarez Gisbert, University Hospital Infanta Sofia, San Sebastian De Los Reyes, Spain

PS02.66 - Moral judgment and social-emotional cognition in paranoia
George J Savulich, University of Cambridge, Cambridge, UK

PS02.67 - Evaluation of a Novel Point of Care Testing Device for Rapid Measurement of Clozapine in Whole Blood
David Taylor, Maudsley Hospital, London, UK

PS02.68 - Increased matrix metalloproteinase-9 and prefrontal deficits in schizophrenia
T. Wilson Woo, McLean Hospital, Belmont, USA

PS02.69 - Long-acting injectable aripiprazole for an elderly patient with concomitant delusional disorder and mild dementia
I-Chun Lee, Department of Psychiatry, Hualien Tzu Chi Hospital, Hualien, Taiwan

PS02.70 - Comparison the effectiveness of long-acting injections of second generation antipsychotic
Eugenio Suarez Gisbert, University Hospital Infanta Sofia, San Sebastian De Los Reyes, Spain

Topic: ADHD

PS02.71 - Sydnocarb treatment has revealed kynurenine involvement in pathogenetic mechanisms of attention deficit hyperactivity disorder.
Marat Uzbekov, Moscow Research Institute of Psychiatry, Moscow, Russia